These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31906840)

  • 1. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
    Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
    Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).
    Hamzah L; Tiraboschi JM; Iveson H; Toby M; Mant C; Cason J; Burling K; Wandolo E; Jendrulek I; Taylor C; Ibrahim F; Kulasegaram R; Teague A; Post FA; Fox J
    Antivir Ther; 2016; 21(4):287-96. PubMed ID: 26460504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
    Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
    South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.
    Overton ET; Chan ES; Brown TT; Tebas P; McComsey GA; Melbourne KM; Napoli A; Hardin WR; Ribaudo HJ; Yin MT
    Ann Intern Med; 2015 Jun; 162(12):815-24. PubMed ID: 26075752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
    J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
    Klassen KM; Kimlin MG; Fairley CK; Emery S; Anderson PH; Ebeling PR;
    Osteoporos Int; 2016 May; 27(5):1737-45. PubMed ID: 26659069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
    Bedimo R; Rosenblatt L; Myers J
    HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
    AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.
    Tebas P; Kumar P; Hicks C; Granier C; Wynne B; Min S; Pappa K
    AIDS; 2015 Nov; 29(18):2459-64. PubMed ID: 26355674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K; Songtaweesin WN; Tepmongkol S; Wongharn P; Kawichai S; Suponsilchai V; Anugulruengkitt S; Puthanakit T;
    J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
    Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W
    Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.